Literature DB >> 16510149

Serum matrix metalloproteinase-2 and increased oxidative stress are associated with carotid atherosclerosis in hemodialyzed patients.

Krystyna Pawlak1, Dariusz Pawlak, Michal Mysliwiec.   

Abstract

Matrix metalloproteinases (MMPs)/their inhibitors (TIMPs) system and elevated oxidative stress (SOX) have been implicated as important factors in atherosclerosis and vascular remodeling. The aim of the present study was to investigate whether MMPs/TIMPs system is associated with SOX in hemodialyzed (HD) patients. We compared the serum levels of metalloproteinases and their inhibitors, markers of SOX, inflammation and atherosclerosis between HD patients (n=40) with and without cardiovascular disease (CVD) and controls (n=20). Cu/Zn superoxide dismutase (Cu/Zn SOD) were elevated (all p<0.001), whereas total lipid peroxide levels were similar in HD patients and controls. The autoantibodies against oxidized LDL (OxLDL-Ab) levels were increased only in patients with CVD (p<0.05). Intima media thickness (IMT) in both CVD and in patients without CVD significantly exceeded those in the control (p<0.001 and p<0.01, respectively). Serum pre-HD values of MMP-2, TIMP-1 and TIMP-2 were significantly increased in HD patients, especially in the CVD group (all p<0.001), and they were associated with those of Cu/Zn SOD, IMT and CVD prevalence. Multiple regression analysis showed that MMP-2, Cu/Zn SOD levels and age independently and significantly predicted elevated IMT in HD patients. Our results suggest the association between SOX and the MMPs/TIMPs system in HD patients, which could represent one of the mechanisms involved in the progression of atherosclerosis in this population.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16510149     DOI: 10.1016/j.atherosclerosis.2006.01.020

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  13 in total

1.  Activation of arterial matrix metalloproteinases leads to vascular calcification in chronic kidney disease.

Authors:  Neal X Chen; Kalisha D O'Neill; Xianming Chen; Kraiwiporn Kiattisunthorn; Vincent H Gattone; Sharon M Moe
Journal:  Am J Nephrol       Date:  2011-07-23       Impact factor: 3.754

2.  Matrix metalloproteinases (MMP-2,9) and their tissue inhibitors (TIMP-1,2) as novel markers of stress response and atherogenesis in children with chronic kidney disease (CKD) on conservative treatment.

Authors:  Kinga Musiał; Danuta Zwolińska
Journal:  Cell Stress Chaperones       Date:  2010-09-06       Impact factor: 3.667

3.  Evolution of shear stress, protein expression, and vessel area in an animal model of arterial dilatation in hemodialysis grafts.

Authors:  Sanjay Misra; Alex A Fu; Khamal D Misra; James F Glockner; Debabrata Mukhopadyay
Journal:  J Vasc Interv Radiol       Date:  2010-01       Impact factor: 3.464

4.  Serum metalloproteinases MMP-2, MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in patients on hemodialysis.

Authors:  Jacek Rysz; Maciej Banach; Robert A Stolarek; Dimitri P Mikhailidis; Aleksandra Cialkowska-Rysz; Lech Pokoca; Mariusz Piechota; Zbigniew Baj
Journal:  Int Urol Nephrol       Date:  2009-12-02       Impact factor: 2.370

5.  Matrix metalloproteinases in cerebral ischemia.

Authors:  Hahn Young Kim; Seol-Heui Han
Journal:  J Clin Neurol       Date:  2006-09-20       Impact factor: 3.077

6.  Matrix metalloproteinases: discrete elevations in essential hypertension and hypertensive end-stage renal disease.

Authors:  Ryan S Friese; Fangwen Rao; Srikrishna Khandrika; Brenda Thomas; Michael G Ziegler; Geert W Schmid-Schönbein; Daniel T O'Connor
Journal:  Clin Exp Hypertens       Date:  2009-10       Impact factor: 1.749

7.  Assessment of myeloperoxidase and oxidative alpha1-antitrypsin in patients on hemodialysis.

Authors:  Hirokazu Honda; Masashi Ueda; Shiho Kojima; Shinichi Mashiba; Yuki Hirai; Nozomu Hosaka; Hiroki Suzuki; Masanori Mukai; Makoto Watanabe; Keiko Takahashi; Kanji Shishido; Tadao Akizawa
Journal:  Clin J Am Soc Nephrol       Date:  2009-01-07       Impact factor: 8.237

8.  The serum levels of MMP-9, MMP-2 and vWF in patients with low doses of urokinase peritoneal dialysis decreased uremia complicated with cerebral infarction.

Authors:  Shu-Jin Wang; Zhong-Sen Qu; Qing-De Zhang; Liang Li; Feng Wang; Bin Zhang; Bang-Li Wu; Yu-Wu Zhao
Journal:  Int J Clin Exp Med       Date:  2015-08-15

9.  Adventitial transduction of lentivirus-shRNA-VEGF-A in arteriovenous fistula reduces venous stenosis formation.

Authors:  Binxia Yang; Rajiv Janardhanan; Pawan Vohra; Eddie L Greene; Santanu Bhattacharya; Sarah Withers; Bhaskar Roy; Evelyn C Nieves Torres; Jaywant Mandrekar; Edward B Leof; Debabrata Mukhopadhyay; Sanjay Misra
Journal:  Kidney Int       Date:  2013-08-07       Impact factor: 10.612

10.  Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study.

Authors:  Anna Gluba-Brzózka; Marta Michalska-Kasiczak; Beata Franczyk; Marek Nocuń; Peter Toth; Maciej Banach; Jacek Rysz
Journal:  Lipids Health Dis       Date:  2016-02-03       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.